Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more

White Paper: Evidence requirements for LPPR List process in France, part 1

Get insights from MTRC White Papers to enhance your understanding of the analysis of five HTAs and strategic recommendations for evidence generation strategy in France

Request free of charge

White Paper: Evidence requirements for LPPR List process in France, part 2

Get insights from MTRC White Papers to discover five recent HAS reports with negative recommendations (March 2024)

Request free of charge
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: French HTA and appropriateness of care: Beyond reimbursement

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. 

In a recent publication, Blanchard et al. explored the role of health technology assessment (HTA) in France beyond reimbursement and access to innovation. The study showed how linking HTA findings with clinical practice guidelines can support decision-making tools, encourage optimal use of drugs and devices, and boost guideline adoption through aligned reimbursement decisions. The authors highlighted that achieving these goals requires a coordinated iterative approach involving healthcare professionals, patients, and other stakeholders.

Access the full-text article here.